EMA Withdrawn: Lumoxiti (moxetumomab pasudotox) — AstraZeneca AB

View source ↗

Summary

Lumoxiti (moxetumomab pasudotox) has been withdrawn from use in the European market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• Lumoxiti (moxetumomab pasudotox-tdfk)

Snippet

Status: Withdrawn. Therapeutic area: Leukemia, Hairy Cell. MAH: AstraZeneca AB. Decision date: 23/07/2021